NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

CSV download of the complete patent data set.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset the Search Filters to go back to the initial display of all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NCI E-767-2013-0-EP-10 Certain Improved Human Bispecific EGFRvIII Antibody Engaging Molecules EP DIV 18215936.8 Pending
NIAID E-154-2017-0-EP-03 NEUTRALIZING ANTIBODIES TO EBOLA VIRUS GLYCOPROTEIN AND THEIR USE EP National Stage 18840136.8 Pending
NHLBI E-120-2016-1-CN-02 HERV-E REACTIVE T CELL RECEPTORS AND METHODS OF USE CN National Stage 201780040513.7 Issued
NHLBI E-120-2016-1-KR-06 HERV-E REACTIVE T CELL RECEPTORS AND METHODS OF USE KR National Stage 10-2018-7037984 Issued
NCI E-186-2007-2-US-41 Papillomavirus Pseudoviruses for Detection and Therapy of Tumors US CON 16/235,152 10814014 Issued PDF
NCI E-227-2017-0-PCT-02 METHOD FOR REMOVING PROTEINS AND UNBOUND LABELS FROM EXTRACELLULAR VESICLE PREPARATIONS PCT PCT PCT/US2018/067913 Expired
NHLBI E-120-2016-1-US-08 HERV-E REACTIVE T CELL RECEPTORS AND METHODS OF USE US National Stage 16/313,712 11779603 Issued PDF
NIAID E-032-2018-0-PCT-02 Universal Influenza Virus Probes For Enrichment Of Influenza Viral Sequences PCT PCT PCT/US2018/067713 Expired
NCI E-141-2008-0-JP-33 Complexes Of IL-15 And IL-15R AIpha And Uses Thereof JP DIV 2018-245439 Abandoned
NCI E-230-2012-0-JP-14 T Cell Receptors Recognizing MHC Class II-Restricted Mage-A3 JP DIV 2018-243703 Issued
NIAID E-081-2013-4-AU-14 Prefusion RSV F Proteins And Their Use AU DIV 2018282476 Issued
NICHD E-120-2015-0-US-59 Method For On-demand Contraception US CON 16/230,802 10772897 Issued PDF
NCI E-767-2013-0-EP-09 Certain Improved Human Bispecific EGFRvIII Antibody Engaging Molecules EP DIV 18215053.2 Pending
NCATS E-043-2017-3-US-02 Pharmaceutical Compositions With Antiflaviviral Activity US National Stage 16/312,316 Pending
NHLBI E-120-2016-1-AU-09 HERV-E REACTIVE T CELL RECEPTORS AND METHODS OF USE AU National Stage 2017286982 Issued
NIAID E-270-2015-0-US-04 Self-assembling Bi-component Nanoparticles For Display Of Coassembled Trimeric Antigens US National Stage 16/312,166 10961283 Issued PDF
NCATS E-189-2016-0-US-03 THIAZOLE DERIVATIVES USEFUL AS MUTANT IDH1 INHIBITORS FOR TREATING CANCER US National Stage 16/312,206 10836759 Issued PDF
NIAID E-174-2016-0-US-03 INHIBITOR OF HEME DEGRADATION FOR USE TO IMPROVE ANTIBIOTIC TREATMENT OF MYCOBACTERIUM TUBERCULOSIS INFECTION US National Stage 16/311,876 Abandoned
NICHD E-247-2009-2-US-09 Dendrimer Based Nanodevices For Therapeutic And Imaging Purposes US CON 16/223,793 10561673 Issued PDF
NCI E-223-2017-0-PCT-02 CHEMICAL ENTITIES FOR LYTIC ACTIVATION OF KSHV AND THERAPEUTIC TARGETING OF VIRAL ENZYMES/PROTEINS PCT PCT PCT/US2018/065601 Expired
NCI E-050-2014-0-SG-15 Cancer Immunotherapy by Delivering Class II MHC Antigens Using a VLP-Replicon SG DIV 10201811190S Pending
NCI E-494-2013-0-US-11 METHODS OF PREPARING ANTI-HUMAN PAPILLOMAVIRUS ANTIGEN T CELLS US CON 16/218,658 Abandoned
NCI E-025-2009-0-US-29 Ratio Based Biomarker Of Survival Utilizing PTEN And Phospho-AKT US CON 16/217,540 11237169 Issued PDF
NCI E-053-2015-1-US-04 MYC G-QUADRUPLEX STABILIZING SMALL MOLECULES AND THEIR USE US DIV 16/218,341 10604499 Issued PDF
NCI E-133-2016-0-EP-03 FLT3-Specific Chimeric Antigen Receptors and Methods Using Same EP National Stage 17729627.4 Pending
NIAID E-007-2015-0-US-16 CD47-targeted Therapies For The Treatment Of Infectious Disease US CON 16/214,507 10723803 Issued PDF
NCI E-114-2011-0-US-05 METHODS OF GROWING TUMOR INFILTRATING LYMPHOCYTES IN GAS-PERMEABLE CONTAINERS US CON 16/211,859 11401503 Issued PDF
CC E-114-2016-0-US-03 TISSUE CHARACTERIZATION WITH ACOUSTIC WAVE TOMOSYNTHESIS US National Stage 16/307,925 Pending
NHLBI E-201-2016-0-KR-06 Annuloplasty Procedures, Related Devices And Methods KR National Stage 10-2018-7035352 Pending
NCI E-059-2013-0-AU-12 Methods of Producing Enriched Populations of Tumor-Reactive T Cells From Tumor AU DIV 2018274874 Issued
NCI E-171-2018-7-HK-08 MODIFIED CELLS AND METHODS OF THERAPY HK EP 18115478.9 Pending
NHLBI E-156-2016-0-EP-05 ADENO-ASSOCIATED VIRUS POLYNUCLEOTIDES, POLYPEPTIDES AND VIRIONS EP National Stage 17793239.9 Issued
NINR E-223-2018-1-PCT-01 Rapid Nucleic Acids Preparation/Sample Preparation Via Hollow Centere Silica Microsphere PCT PCT COMB PCT/US2018/063663 Expired
NCI E-239-2017-0-EP-09 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS EP National Stage 18830062.8 Pending
NCI E-238-2017-0-PCT-02 METHODS OF ENRICHING CELL POPULATIONS FOR CANCER-SPECIFIC T CELLS USING IN VITRO STIMULATION OF MEMORY T CELLS PCT PCT PCT/US2018/063563 Expired
NCI E-239-2017-0-PCT-02 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS PCT PCT PCT/US2018/063581 Expired
NCI E-239-2017-0-AU-03 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS AU National Stage 2018378200 Pending
NCI E-239-2017-0-BR-04 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS BR National Stage BR112020011111-2 Pending
NCI E-239-2017-0-MX-14 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS MX National Stage MX/a/2020/005765 Pending
NCI E-239-2017-0-NZ-15 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS NZ National Stage 765440 Pending
NCI E-239-2017-0-IN-11 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS IN National Stage 202047026991 Pending
NCI E-239-2017-0-IL-10 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS IL National Stage 275031 Pending
NCI E-239-2017-0-SG-16 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS SG National Stage 11202005236Q Pending
NCI E-239-2017-0-KR-13 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS KR National Stage 2020-7019185 Pending
NCI E-239-2017-0-CR-07 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS CR National Stage 2020-0287 Pending
NCI E-239-2017-0-CA-05 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS CA National Stage 3084246 Pending
NCI E-239-2017-0-CN-06 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS CN National Stage 201880087270.7 Pending
NCI E-040-2012-0-IL-30 Chimeric Antigen Receptors Targeting B-cell Maturation Antigen IL DIV 263417 Issued
NCI E-162-2014-0-IT-24 HUMAN MONOCLONAL ANTIBODIES AGAINST EPHA4 AND THEIR USE IT EP 18209632.1 Issued
NCI E-162-2014-0-BE-18 HUMAN MONOCLONAL ANTIBODIES AGAINST EPHA4 AND THEIR USE BE EP 18209632.1 Issued